How to Build an FDA-Compliant Pharmacovigilance and Post-Market Safety System For pharmaceutical and biologics manufacturers, the responsibility for patient safety extends far beyond product approval. The U.S. Food and Drug Administration (FDA) requires continuous post-marketing surveillance to ensure that risks identified during development—and new ones emerging in the market—are monitored, evaluated, and mitigated. An effective pharmacovigilance (PV) program integrates scientific vigilance with regulatory discipline, forming the backbone of post-market compliance. This three-part guide explains how to align your global PV system with FDA expectations in , covering statutory foundations, operational structure, signal detection, and risk-management best practices. 1. Regulatory Framework…

21 CFR postmarketing safety reporting requirements for NDA and ANDA holders 21 CFR Postmarketing Safety Reporting Requirements for NDA and ANDA Holders Postmarketing safety reporting is a critical aspect of ensuring drug safety and efficacy after a product has been released into the market. This process is governed by the regulations outlined in 21 CFR Parts 314 and 600, which stipulate the obligations of New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) holders. In this tutorial, we will explore the comprehensive requirements for postmarketing safety reporting under US pharmacovigilance regulations. Understanding Postmarketing Safety Reporting Requirements Postmarketing safety reporting…

Integrating REMS Obligations with Routine US Pharmacovigilance Operations The integration of Risk Evaluation and Mitigation Strategies (REMS) with routine US pharmacovigilance operations is a critical task for professionals involved in drug safety and regulatory compliance. This guide aims to provide a thorough step-by-step tutorial on understanding and implementing the US pharmacovigilance requirements, particularly around REMS obligations, postmarketing safety reporting, and compliance with 21 CFR regulations. Understanding REMS and Its Importance in Pharmacovigilance REMS are safety strategies designed to ensure that the benefits of a drug outweigh its risks. They are often required by the FDA when a drug has serious…

End to end FAERS case reporting workflow design for US pharma companies End to end FAERS case reporting workflow design for US pharma companies Pharmaceutical companies operating in the United States must navigate through a complex regulatory landscape, particularly when it comes to pharmacovigilance. The Food and Drug Administration (FDA) mandates that companies report adverse events and other safety-related findings, chiefly through the FDA Adverse Event Reporting System (FAERS). This article provides a comprehensive step-by-step guide to designing an effective FAERS case reporting workflow, in accordance with US pharmacovigilance requirements, particularly focusing on 21 CFR safety reporting. Understanding FAERS and…

How to Build a US PV Compliance Roadmap Around FAERS and 21 CFR 314.80 Building a compliance roadmap for pharmacovigilance (PV) is essential for ensuring the safety of pharmaceutical products post-approval. The United States Food and Drug Administration (FDA) sets forth specific regulations that guide the reporting of adverse events, and adherence to these requirements is critical for pharmaceutical companies operating within the US, UK, and EU markets. This article will provide a step-by-step tutorial on how to construct a compliance roadmap centered around the FDA’s Adverse Event Reporting System (FAERS) and the regulations outlined in 21 CFR 314.80. Understanding…

US Pharmacovigilance Requirements Explained: FAERS, REMS, and 21 CFR Safety Reporting Understanding US Pharmacovigilance Requirements: FAERS, REMS, and 21 CFR Safety Reporting Pharmacovigilance is a critical component of drug safety management in the pharmaceutical industry, focusing on the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. In the United States, the regulatory framework governing pharmacovigilance is primarily shaped by the Food and Drug Administration (FDA) under 21 CFR Parts 314.80 and the implementation of the FDA Adverse Event Reporting System (FAERS) and Risk Evaluation and Mitigation Strategies (REMS). This article serves as a comprehensive tutorial…

Case study lessons from FDA warning letters on pharmacovigilance compliance Case Study Lessons from FDA Warning Letters on Pharmacovigilance Compliance In today’s regulatory landscape, pharmacovigilance compliance is critical for ensuring patient safety and maintaining the integrity of pharmaceutical products. This article will provide a detailed tutorial on lessons learned from FDA warning letters related to US pharmacovigilance requirements. The focus will be on understanding the key components of effective pharmacovigilance systems, particularly regarding FAERS, REMS, and 21 CFR safety reporting. Understanding the US Pharmacovigilance Requirements In the United States, pharmaceutical companies are subject to strict US pharmacovigilance requirements governed primarily…

Designing SOPs for US ICSR Submission, Follow Up and Nullification The implementation of Standard Operating Procedures (SOPs) for Individual Case Safety Reports (ICSRs) is crucial for compliance with US pharmacovigilance requirements. Pharmacovigilance encompasses the monitoring, assessment, and reporting of adverse effects related to pharmaceutical products. This tutorial provides a comprehensive step-by-step approach to designing effective SOPs focused on ICSR submission, follow-up, and nullification, ensuring adherence to pivotal regulations such as 21 CFR 314.80 and the reporting systems such as FAERS. Understanding the Regulatory Landscape for Pharmacovigilance Pharmacovigilance in the United States is regulated by the FDA and encompasses a range…

Labelling changes, REMS updates and FAERS trends what FDA expects to see Introduction to US Pharmacovigilance Requirements The U.S. Food and Drug Administration (FDA) has a well-defined regulatory framework for pharmacovigilance, which includes monitoring the safety of medications post-marketing. A crucial component of this framework involves reporting adverse events through the FDA Adverse Event Reporting System (FAERS). Proper understanding of the US pharmacovigilance requirements, including labeling changes, Risk Evaluation and Mitigation Strategies (REMS), and safety reporting as per 21 CFR 314.80, is essential for compliance and improving patient safety. Pharma professionals, including those in clinical operations, regulatory affairs, and medical…

Governance models for US safety sign off and FDA safety reporting Governance models for US safety sign off and FDA safety reporting Pharmaceutical and biotech companies play a critical role in ensuring that medicinal products are safe and effective. In the United States, compliance with the US pharmacovigilance requirements set forth by the FDA is paramount for protecting public health. This comprehensive guide will outline the governance models for US safety sign off and FDA safety reporting, emphasizing the importance of postmarketing safety reporting, including specifics on the FAERS system, REMS, and relevant regulatory citations under 21 CFR. Understanding US…